ERBB2 c.3139C>T ;(p.H1047Y)

Variant ID: 17-37883236-C-T

NM_004448.2(ERBB2):c.3139C>T;(p.H1047Y)

This variant was identified in 15 publications

View GRCh38 version.




Publications:


Genomics-Driven Precision Medicine in Pediatric Solid Tumors.

Cancers
Suthapot, Praewa P; Chiangjong, Wararat W; Chaiyawat, Parunya P; Choochuen, Pongsakorn P; Pruksakorn, Dumnoensun D; Sangkhathat, Surasak S; Hongeng, Suradej S; Anurathapan, Usanarat U; Chutipongtanate, Somchai S
Publication Date: 2023-02-23

Variant appearance in text: ERBB2: H1047Y
PubMed Link: 36900212
Variant Present in the following documents:
  • cancers-15-01418.pdf
View BVdb publication page



PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Jco Precision Oncology
Rasti, Aryana R AR; Guimaraes-Young, Amy A; Datko, Farrah F; Borges, Virginia F VF; Aisner, Dara L DL; Shagisultanova, Elena E
Publication Date: 2022-03

Variant appearance in text: HER2: H1047Y
PubMed Link: 35357905
Variant Present in the following documents:
  • po-6-e2100370.pdf
View BVdb publication page



Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus.

Cancers
Vestergaard, Lau K LK; Oliveira, Douglas N P DNP; Poulsen, Tim S TS; Høgdall, Claus K CK; Høgdall, Estrid V EV
Publication Date: 2021-10-18

Variant appearance in text: ERBB2: H1047Y
PubMed Link: 34680378
Variant Present in the following documents:
  • Main text
  • cancers-13-05230.pdf
View BVdb publication page



PIKfyve activity is required for lysosomal trafficking of tau aggregates and tau seeding.

The Journal Of Biological Chemistry
Soares, Alberto Carpinteiro AC; Ferreira, Andreia A; Mariën, Jonas J; Delay, Charlotte C; Lee, Edward E; Trojanowski, John Q JQ; Moechars, Dieder D; Annaert, Wim W; De Muynck, Louis L
Publication Date: 2021

Variant appearance in text: ERBB2: H1047Y
PubMed Link: 33831417
Variant Present in the following documents:
  • mmc1.pdf
View BVdb publication page



How to use liquid biopsies to treat patients with cancer.

Esmo Open
De Mattos-Arruda, L L; Siravegna, G G
Publication Date: 2021-04

Variant appearance in text: HER2: H1047Y
PubMed Link: 33647598
Variant Present in the following documents:
  • main.pdf
View BVdb publication page



The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.

European Urology
Deek, Matthew P MP; Van der Eecken, Kim K; Phillips, Ryan R; Parikh, Neil R NR; Isaacsson Velho, Pedro P; Lotan, Tamara L TL; Kishan, Amar U AU; Maurer, Tobias T; , ; Boutros, Paul C PC; Hovens, Christopher C; Abramowtiz, Matthew M; Pollack, Alan A; Desai, Neil N; Stish, Bradley B; Feng, Felix Y FY; Eisenberger, Mario M; Carducci, Michael M; Pienta, Kenneth J KJ; Markowski, Mark M; Paller, Channing J CJ; Antonarakis, Emmanuel S ES; Berlin, Alejandro A; Ost, Piet P; Tran, Phuoc T PT
Publication Date: 2021-11

Variant appearance in text: ERBB2: 3139C>T
PubMed Link: 33419682
Variant Present in the following documents:
  • NIHMS1793749-supplement-22.pdf
View BVdb publication page



Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis.

Plos One
Uesato, Yasunori Y; Sasahira, Naoki N; Ozaka, Masato M; Sasaki, Takashi T; Takatsuki, Mitsuhisa M; Zembutsu, Hitoshi H
Publication Date: 2020

Variant appearance in text: ERBB2: H1047Y
PubMed Link: 32614932
Variant Present in the following documents:
  • pone.0235623.s001.xlsx, sheet 1
View BVdb publication page



Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.

Plos One
Patel, Ravi K RK; Weir, Mark C MC; Shen, Kexin K; Snyder, Daniel D; Cooper, Vaughn S VS; Smithgall, Thomas E TE
Publication Date: 2019

Variant appearance in text: ERBB2: H1047Y
PubMed Link: 31790499
Variant Present in the following documents:
  • pone.0225887.s012.pdf
View BVdb publication page



Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.

Therapeutic Advances In Medical Oncology
Milewska, Malgorzata M; Cremona, Mattia M; Morgan, Clare C; O'Shea, John J; Carr, Aoife A; Vellanki, Sri H SH; Hopkins, Ann M AM; Toomey, Sinead S; Madden, Stephen F SF; Hennessy, Bryan T BT; Eustace, Alex J AJ
Publication Date: 2018

Variant appearance in text: ERBB2: H1047Y
PubMed Link: 29383036
Variant Present in the following documents:
  • 10.1177_1758834017746040.pdf
View BVdb publication page



Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate.

Esmo Open
Ree, Anne Hansen AH; Russnes, Hege G HG; Heinrich, Daniel D; Dueland, Svein S; Boye, Kjetil K; Nygaard, Vigdis V; Silwal-Pandit, Laxmi L; Østrup, Olga O; Hovig, Eivind E; Nygaard, Vegard V; Rødland, Einar A EA; Nakken, Sigve S; Øien, Janne T JT; Johansen, Christin C; Bergheim, Inger R IR; Skarpeteig, Veronica V; Sathermugathevan, Menaka M; Sauer, Torill T; Lund-Iversen, Marius M; Beiske, Klaus K; Nasser, Salah S; Julsrud, Lars L; Reisse, Claudius H CH; Ruud, Espen A EA; Flørenes, Vivi Ann VA; Hagene, Kirsten T KT; Aas, Eline E; Lurås, Hilde H; Johnsen-Soriano, Siv S; Geitvik, Gry A GA; Lingjærde, Ole Christian OC; Børresen-Dale, Anne-Lise AL; Mælandsmo, Gunhild M GM; Flatmark, Kjersti K
Publication Date: 2017

Variant appearance in text: ERBB2: H1047Y
PubMed Link: 28761742
Variant Present in the following documents:
  • esmoopen-2017-000158supp002.pdf
View BVdb publication page



ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

Nature Communications
Williamson, Chris T CT; Miller, Rowan R; Pemberton, Helen N HN; Jones, Samuel E SE; Campbell, James J; Konde, Asha A; Badham, Nicholas N; Rafiq, Rumana R; Brough, Rachel R; Gulati, Aditi A; Ryan, Colm J CJ; Francis, Jeff J; Vermulen, Peter B PB; Reynolds, Andrew R AR; Reaper, Philip M PM; Pollard, John R JR; Ashworth, Alan A; Lord, Christopher J CJ
Publication Date: 2016-12-13

Variant appearance in text: ERBB2: H1047Y
PubMed Link: 27958275
Variant Present in the following documents:
  • ncomms13837-s4.xlsx, sheet 1
View BVdb publication page



Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.

Acs Chemical Biology
Terai, Hideki H; Tan, Li L; Beauchamp, Ellen M EM; Hatcher, John M JM; Liu, Qingsong Q; Meyerson, Matthew M; Gray, Nathanael S NS; Hammerman, Peter S PS
Publication Date: 2015-12-18

Variant appearance in text: ERBB2: H1047Y
PubMed Link: 26390252
Variant Present in the following documents:
  • cb5b00655_si_001.pdf
View BVdb publication page



Type-specific cell line models for type-specific ovarian cancer research.

Plos One
Anglesio, Michael S MS; Wiegand, Kimberly C KC; Melnyk, Nataliya N; Chow, Christine C; Salamanca, Clara C; Prentice, Leah M LM; Senz, Janine J; Yang, Winnie W; Spillman, Monique A MA; Cochrane, Dawn R DR; Shumansky, Karey K; Shah, Sohrab P SP; Kalloger, Steve E SE; Huntsman, David G DG
Publication Date: 2013

Variant appearance in text: ERBB2: H1047Y
PubMed Link: 24023729
Variant Present in the following documents:
  • pone.0072162.s005.pdf
View BVdb publication page



Oncogene Mutation Survey in MPNST Cell Lines Enhances the Dominant Role of Hyperactive Ras in NF1 Associated Pro-Survival and Malignancy.

Translational Oncogenomics
Sun, Daochun D; Tainsky, Michael A MA; Haddad, Ramsi R
Publication Date: 2012

Variant appearance in text: ERBB2: H1047Y
PubMed Link: 22346343
Variant Present in the following documents:
  • tog-5-2012-001.pdf
View BVdb publication page



Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1.

Acs Medicinal Chemistry Letters
Deng, Xianming X; Yang, Qingkai Q; Kwiatkowski, Nicholas N; Sim, Taebo T; McDermott, Ultan U; Settleman, Jeffrey E JE; Lee, Jiing-Dwan JD; Gray, Nathanael S NS
Publication Date: 2011-03-10

Variant appearance in text: ERBB2: H1047Y
PubMed Link: 21412406
Variant Present in the following documents:
  • ml100304b_si_002.pdf
View BVdb publication page